Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

Medline Inc. has registered a planned initial public offering with the US Securities and Exchange Commission that could be worth up to $5bn. The company says it’s the world’s largest provider of medical and surgical supplies.

After a slight delay in closing the deal, Zimmer now has Monogram in-house. For shareholders hoping for CVR payouts, the first one looks fairly achievable, the rest increasingly less so. The vagaries of FDA clearance and market performance offer significant challenges to the new robotics powerhouse.

J&J announced the separation of its orthopedics unit into a stand-alone company. The firm as a whole expects sales growth of over 5% in 2026. Gabelli analyst Jennie Tsai foresees more consolidation in orthopedics led by Zimmer Biomet, Stryker and DePuy as well as more acquisitions.